<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986296</url>
  </required_header>
  <id_info>
    <org_study_id>OCD001</org_study_id>
    <nct_id>NCT01986296</nct_id>
  </id_info>
  <brief_title>ExAblate Treatment of Medication Refractory Obsessive Compulsive Disorder</brief_title>
  <official_title>A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound Treatment of Medication-Refractory OCD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this prospective, non-randomized, single-arm, single site, feasibility study is&#xD;
      to develop and collect data to evaluate the safety and initial effectiveness of this&#xD;
      treatment using this ExAblate transcranial System in the treatment of Medication-Refractory&#xD;
      OCD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and initial effectiveness of MRI-guided&#xD;
      focused ultrasound thermal ablation of a designated area in the brain of patients suffering&#xD;
      from medication-refractory OCD, using the ExAblate transcranial system.&#xD;
&#xD;
      The ExAblate system is a medical device that involves a focused ultrasound system and an MRI&#xD;
      scanner. ExAblate delivers a pulse of focused ultrasound energy, or sonication, to the&#xD;
      targeted tissue. For OCD Patients: one or more thermal lesion will be created on one of the&#xD;
      following targets: Anterior cingulate cortex, Anterior Limb of internal Capsule, Ventral&#xD;
      Striatum or Subgenual Cingulate Cortex.&#xD;
&#xD;
      The treatment begins with a series of standard diagnostic MR images to identify the location&#xD;
      and shape of tumor to be treated. The ExAblate computer uses the physician's designation of&#xD;
      the target volume to plan the best way to cover the target volume with small spots called&#xD;
      &quot;sonications&quot;. These treatment spots are cylinder shaped. Their size depends on sonication&#xD;
      power and duration. During the treatment, a specific MR scan, which can be processed to&#xD;
      identify changes in tissue temperature, provides a thermal map of the treatment volume to&#xD;
      confirm the therapeutic effect. The thermal map is used to monitor the treatment in progress,&#xD;
      and confirm that the ablation is proceeding according to plan, thus closing the therapy loop.&#xD;
&#xD;
      The ExAblate transcranial operates a helmet-shaped transducer (currently utilizing&#xD;
      1000-element phased array transducer) positioned above the subject head. The ExAblate&#xD;
      transcranial system also includes means to immobilize the subject head, cool the interface&#xD;
      water, and software for CT analysis and phase correction computation.&#xD;
&#xD;
      After informed consent and screening, eligible subjects will proceed to the treatment. All&#xD;
      subjects will be followed at Day 1, 7 days, 1 month, 6 months and 1, 2 and 3 years. At follow&#xD;
      up visits, patients will be evaluated for general health, neurological changes (including&#xD;
      MMSE exam),and efficacy measurements as well as for device/procedure related adverse events&#xD;
      that may have occurred during the follow-up period. Six (6) month and 1, 2 and 3 year follow&#xD;
      up visits will also include Full Battery Cognitive/Neurological Testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of the ExAblate Transcranial MRgFUS treatment of medication-refractory OCD</measure>
    <time_frame>Participants will be followed from the date of treatment until study completion, up to 36 months</time_frame>
    <description>Effectiveness of the ExAblate Transcranial MR-guided Focused Ultrasound (MRgFUS) treatment of medication-refractory OCD will be determined using the Yale-Brown Obsessive-Compulsive Disorder Scale (Y-BOCS), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A) from examinations at baseline and through 6-Months post-ExAblate treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device or procedure related Adverse Events reported</measure>
    <time_frame>36 month</time_frame>
    <description>Safety of the ExAblate transcranial treatment will be determined by an evaluation of the incidence and severity of device and procedure related complications from the first / treatment day visit through the 6-Months post-treatment time point. All Adverse Events (AEs) will be reported and categorized by investigators as definitely, probably, possibly, or unrelated to the device, procedure, or post-surgical changes in neurological status. Alternative treatments resulting from post-surgical changes in neurological status will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Medication-refractory Obsessive Compulsive Disorder (OCD)</condition>
  <arm_group>
    <arm_group_label>ExAblate Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ExAblate Transcranial MRgFUS System</intervention_name>
    <description>Treatment with the ExAblate Transcranial MRgFUS System.</description>
    <arm_group_label>ExAblate Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, between 18 and 65 years, inclusive&#xD;
&#xD;
          2. Subjects who are able and willing to give consent and able to attend all study visits&#xD;
&#xD;
          3. OCD refractory to adequate trials of medication and behavioral therapy by psychiatrist&#xD;
             (more than 12 weeks at the maximum tolerated dose with more than two types of&#xD;
             serotonin reuptake inhibitors).&#xD;
&#xD;
          4. Designated Ablation Targets can be target by the ExAblate device. Designated Ablation&#xD;
             Targets must be apparent on MRI such that targeting can be performed with direct&#xD;
             visualization.&#xD;
&#xD;
          5. Able to communicate sensations during the ExAblate MRgFUS treatment&#xD;
&#xD;
          6. Definitive diagnosis of OCD, according to the criteria of the Diagnostic and&#xD;
             Statistical Manual of Mental Disorder fourth edition (DSM-IV), with disease duration&#xD;
             of more than 3 years, with diagnosed psychosocial dysfunction. (The diagnosis of OCD&#xD;
             would be done by psychiatrist)&#xD;
&#xD;
          7. A score on the Y-BOCS of more than 28.&#xD;
&#xD;
          8. OCD medication regimen is stable for at least 30 days before enrolment&#xD;
&#xD;
          9. Patients with diagnosed psychosocial dysfunction influenced by OCD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with unstable cardiac status including:&#xD;
&#xD;
               1. Unstable angina pectoris on medication&#xD;
&#xD;
               2. Patients with documented myocardial infarction within last 40 days to protocol&#xD;
                  entry&#xD;
&#xD;
               3. Congestive heart failure NYHA Class IV&#xD;
&#xD;
          2. Patients exhibiting any behavior(s) consistent with ethanol or substance abuse as&#xD;
             defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the&#xD;
             following occurring within a 12 month period:&#xD;
&#xD;
               -  Recurrent substance use resulting in a failure to fulfill major role obligations&#xD;
                  at work, school, or home (such as repeated absences or poor work performance&#xD;
                  related to substance use; substance-related absences, suspensions, or expulsions&#xD;
                  from school; or neglect of children or household).&#xD;
&#xD;
               -  Recurrent substance use in situations in which it is physically hazardous (such&#xD;
                  as driving an automobile or operating a machine when impaired by substance use)&#xD;
&#xD;
               -  Recurrent substance-related legal problems (such as arrests for substance related&#xD;
                  disorderly conduct)&#xD;
&#xD;
               -  Continued substance use despite having persistent or recurrent social or&#xD;
                  interpersonal problems caused or exacerbated by the effects of the substance (for&#xD;
                  example, arguments with spouse about consequences of intoxication and physical&#xD;
                  fights).&#xD;
&#xD;
          3. Severe hypertension (diastolic BP &gt; 100 on medication)&#xD;
&#xD;
          4. Patients with standard contraindications for MR imaging such as non-MRI compatible&#xD;
             implanted metallic devices including cardiac pacemakers, size limitations, etc.&#xD;
&#xD;
          5. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium/Magnevist)&#xD;
             including advanced kidney disease&#xD;
&#xD;
          6. Patients receiving dialysis&#xD;
&#xD;
          7. History of abnormal bleeding and/or coagulopathy&#xD;
&#xD;
          8. Receiving anticoagulant (e.g. Warfarin) or antiplatelet (e.g. aspirin) therapy within&#xD;
             one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage&#xD;
             (e.g. Avastin) within one month of scheduled focused ultrasound procedure&#xD;
&#xD;
          9. Active or suspected, acute or chronic uncontrolled infection or known life-threatening&#xD;
             systemic disease&#xD;
&#xD;
         10. History of intracranial hemorrhage&#xD;
&#xD;
         11. Cerebrovascular disease (multiple CVA or CVA within 6 months)&#xD;
&#xD;
         12. Evidence for calcifications that might interfere with treatment safety (per CT)&#xD;
&#xD;
         13. Individuals who are not able or willing to tolerate the required prolonged stationary&#xD;
             supine position during treatment (can be up to 4 hrs of total table time.)&#xD;
&#xD;
         14. Symptoms and signs of increased intracranial pressure (e.g. headache, nausea,&#xD;
             vomiting, lethargy, and papilledema)&#xD;
&#xD;
         15. Patients unable to communicate with the investigator and staff&#xD;
&#xD;
         16. Presence of any other neurodegenerative disease like Parkinson-plus syndromes&#xD;
             suspected on neurological examination. These include:&#xD;
&#xD;
               1. Multisystem atrophy&#xD;
&#xD;
               2. Progressive supranuclear palsy&#xD;
&#xD;
               3. Dementia with Lewy bodies&#xD;
&#xD;
               4. Alzheimer's disease&#xD;
&#xD;
         17. Subjects diagnosed with idiopathic Parkinson's disease.&#xD;
&#xD;
         18. Presence of significant cognitive impairment as determined with a score â‰¤ 24 on the&#xD;
             Mini Mental Status Examination (MMSE)&#xD;
&#xD;
         19. History of immunocompromise, including patient who are HIV positive&#xD;
&#xD;
         20. Patients with a history of seizures within the past year&#xD;
&#xD;
         21. Patients with risk factors for intraoperative or postoperative bleeding:&#xD;
&#xD;
               1. Platelet count less than 100,000 per cubic millimeter&#xD;
&#xD;
               2. PT &gt; 14&#xD;
&#xD;
               3. PTT &gt; 36&#xD;
&#xD;
               4. INR &gt; 1.3&#xD;
&#xD;
               5. Documented coagulopathy&#xD;
&#xD;
               6. Patients receiving medications that are known to induce or contribute to&#xD;
                  Hemorrhages&#xD;
&#xD;
         22. Patients with any types of brain tumors, including metastases&#xD;
&#xD;
         23. Any illness that in the investigator's opinion preclude participation in this study&#xD;
&#xD;
         24. Pregnancy or lactation&#xD;
&#xD;
         25. Patients who have had deep brain stimulation or a prior stereotactic ablation of&#xD;
             Designated Ablation Target&#xD;
&#xD;
         26. OCD medication regimen is not stable for at least 30 days before enrolment&#xD;
&#xD;
         27. Legal incapacity or limited legal capacity&#xD;
&#xD;
         28. Subjects with remarkable atrophy and poor healing capacity of the scalp (&gt; 30% of the&#xD;
             skull area traversed by the sonication pathway)&#xD;
&#xD;
         29. Are participating or have participated in another clinical trial in the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Woo Chang, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.insightec.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 11, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

